利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

52 条记录 (耗时 0.089 秒)

    INDAZOLINONE COMPOSITIONS USEFUL AS KINASE INHIBITORS
    32.
    发明申请
    INDAZOLINONE COMPOSITIONS USEFUL AS KINASE INHIBITORS 有权
    恩佐酮组合物可用作激酶抑制剂

    公开(公告)号：US20090048250A1

    公开(公告)日：2009-02-19

    申请号：US11841233

    申请日：2007-08-20

    申请人： Alex Aronov ,  David J. Lauffer ,  Huan Qiu Li ,  Ronald Charles Tomlinson ,  Pan Li

    发明人： Alex Aronov ,  David J. Lauffer ,  Huan Qiu Li ,  Ronald Charles Tomlinson ,  Pan Li

    IPC分类号： A61K31/5377 ,  C07D231/54 ,  A61K31/4152 ,  C07D471/04 ,  C07D413/04 ,  A61K31/437 ,  C07D403/02 ,  A61K31/53

    CPC分类号： C07D403/14 ,  C07D407/14 ,  C07D409/14 ,  C07D471/04

    摘要： The present invention provides compounds of formula I: These compounds, and pharmaceutically acceptable compositions thereof, are useful generally as kinase inhibitors, particularly as inhibitors of PRAK, GSK3, ERK2, CDK2, MK2, SRC, SYK, and Aurora-2. Accordingly, compounds and compositions of the invention are useful for treating or lessening the severity of a variety of disorders, including, but not limited to, heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, allergic diseases, autoimmune diseases, destructive bone disorders such as osteoporosis, proliferative disorders, infectious diseases and viral diseases.

    摘要翻译： 本发明提供式I化合物：这些化合物及其药学上可接受的组合物通常用作激酶抑制剂，特别是作为PRAK，GSK3，ERK2，CDK2，MK2，SRC，SYK和Aurora-2的抑制剂。 因此，本发明的化合物和组合物可用于治疗或减轻各种障碍的严重性，包括但不限于心脏病，糖尿病，阿尔茨海默氏病，免疫缺陷病症，炎性疾病，过敏性疾病，自身免疫疾病，破坏性 骨质疏松症，增殖性疾病，感染性疾病和病毒性疾病等骨骼疾病。

    Inhibitors of interleukin-1&bgr; converting enzyme
    36.
    发明授权
    Inhibitors of interleukin-1&bgr; converting enzyme 失效
    白细胞介素-1β转换酶抑制剂

    公开(公告)号：US06329365B1

    公开(公告)日：2001-12-11

    申请号：US09326495

    申请日：1999-06-04

    申请人： Julian M. C. Golec ,  David J. Lauffer ,  David J. Livingston ,  Michael D. Mullican ,  Mark A. Murcko ,  Philip L. Nyce ,  Andrea L. C. Robidoux ,  Marion W. Wannamaker

    发明人： Julian M. C. Golec ,  David J. Lauffer ,  David J. Livingston ,  Michael D. Mullican ,  Mark A. Murcko ,  Philip L. Nyce ,  Andrea L. C. Robidoux ,  Marion W. Wannamaker

    IPC分类号： A61K3155

    CPC分类号： C07K5/0821 ,  A61K38/00 ,  C07K5/0202 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/389 ,  Y02A50/475

    摘要： The present invention relates to novel classes of compounds which are inhibitors of interleukin-1&bgr; converting enzyme (“ICE”). This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against interleukin-1-(“IL-1”), apoptosis-, interferon-&ggr; inducing factor-(IGIF), interferon-&ggr;-(“IFN-&ggr;”) mediated diseases, excess dietary alcohol intake diseases, or viral diseases, including inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, and degenerative diseases. This invention also relates to methods for inhibiting ICE activity and decreasing IGIF production and IFN-&ggr; production and methods for treating interleukin-1, apoptosis- and interferon-&ggr;-mediated diseases using the compounds and compositions of this invention. This invention also relates to methods of preparing the compounds of this invention.

    摘要翻译： 本发明涉及作为白细胞介素-1β转换酶（“ICE”）抑制剂的新型化合物。 本发明还涉及包含这些化合物的药物组合物。 本发明的化合物和药物组合物特别适用于抑制ICE活性，因此可有利地用作抗白细胞介素-1-（“IL-1”），细胞凋亡，干扰素-γ诱导因子（IGIF） 干扰素-γ-（“IFN-γ”）介导的疾病，过度饮食酒精摄入疾病或病毒性疾病，包括炎性疾病，自身免疫疾病，破坏性骨病，增殖性疾病，感染性疾病和退行性疾病。 本发明还涉及使用本发明的化合物和组合物来抑制ICE活性和降低IGIF产生和IFN-γ产生的方法以及用于治疗白细胞介素-1，凋亡和干扰素-γ介导的疾病的方法。 本发明还涉及制备本发明化合物的方法。